Menu

Press Releases

Date Summary View
Toggle Summary RedHill Biopharma Announces Closing of $25 Million Bought Deal Offering
TEL AVIV, Israel and RALEIGH, N.C. , Jan. 14, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the closing of its previously announced underwritten offering of 3,188,776 American Depositary Shares (ADSs) ...
View HTML
Toggle Summary RedHill Biopharma Increases Previously Announced Bought Deal to $25 Million
TEL AVIV, Israel and RALEIGH, N.C. , Jan. 12, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that due to demand, the underwriter has agreed to increase the size of the previously announced offering and ...
View HTML
Toggle Summary RedHill Biopharma Announces $10 Million Bought Deal Offering
TEL AVIV, Israel and RALEIGH, N.C. , Jan. 11, 2021 /PRNewswire/ --  RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has entered into an underwriting agreement with H.C. ...
View HTML
Toggle Summary RedHill's Partner Cosmo Pharmaceuticals Successfully Completes Phase 2 Study of Rifamycin SV-MMX 600mg in IBS-D
TEL AVIV, Israel and RALEIGH, N.C ,, Jan. 11, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or "the Company"), a specialty biopharmaceutical company, today reported that its partner, Cosmo Pharmaceuticals (SIX: COPN) ("Cosmo"), announced that it had successfully completed ...
View HTML
Toggle Summary RedHill Biopharma's RHB-204 Granted FDA Fast Track Designation for NTM Disease
U.S. Phase 3 study underway to evaluate RHB-204 as a first-line, stand-alone, oral treatment for pulmonary NTM disease - a rare condition with no FDA-approved first-line therapy FDA Fast Track designation, together with previously granted QIDP designation, provides RHB-204 with eligibility for ...
View HTML
Toggle Summary RedHill Biopharma Announces Positive Top-Line Safety and Efficacy Data from Phase 2 COVID-19 Study of Opaganib
Preliminary data from the non-powered U.S. Phase 2 study of 40 hospitalized patients shows that orally-administered opaganib was safe, with no material safety differences between opaganib and control arms Consistent trends demonstrate greater improvement in reducing oxygen requirement by end of ...
View HTML
Toggle Summary RedHill's Phase 2/3 COVID-19 Study of Opaganib Passes Second DSMB with Unanimous Recommendation to Continue
Independent DSMB unanimously recommends continuation of the global Phase 2/3 study of orally-administered opaganib in severe COVID-19 based on review of unblinded safety data from 155 treated patients Top-line data from the 270-patient global Phase 2/3 COVID-19 study expected Q1/2021 Top-line data ...
View HTML
Toggle Summary RedHill's Phase 2/3 COVID-19 Candidate Opaganib Reduces ARDS-Related Blood Clotting in Preclinical Model
Acute respiratory distress syndrome (ARDS)-induced thrombosis (blood clotting) may occur in up to one-third of COVID-19 patients requiring ICU admission and is a contributing cause of mortality Opaganib demonstrated reduced thrombosis in a preclinical model of ARDS Opaganib has also been shown to ...
View HTML
Toggle Summary RedHill Biopharma Added to NASDAQ Biotechnology Index
TEL AVIV, Israel and RALEIGH, N.C. , Dec. 14, 2020 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that the company was selected for addition to the NASDAQ Biotechnology Index (NASDAQ: NBI). ...
View HTML
Toggle Summary RedHill Biopharma Extends Talicia® Unrestricted National and Regional Commercial Coverage to Over 40 Million Additional Americans
Talicia® unrestricted access in the U.S. now extends to over 70% of commercial lives covered Approximately 35% of Americans are affected by H. pylori infection, a Group 1 carcinogen and the strongest risk factor for gastric cancer; eradication of H. pylori has been shown to reduce the risk of ...
View HTML